English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The phase III MPACT trial demonstrated the superiority of gemcitabine plus nab-paclitaxel (NABGEM) versus gemcitabine alone in previously untreated patients with metastatic pancreatic cancer (mPC). The aim of this study was to evaluate the responses in terms of efficacy and safety in patients treated with more than 6 cycles of chemotherapy. From January 2015 to December 2018, patients with mPC receiving first-line treatment with NABGEM were included in a multicentre retrospective observational study. Exploratory analyses of efficacy and safety were performed. The cohort included 153 patients with performance status of 1. The median overall survival and progression-free survival were 20 months (hazard ratio [HR] 0.28, 95% confidence interval [CI]: 0.17–0.44) and 10 months (HR 0.24 95% CI: 0.16–0.38) respectively, in patients who received &gt;6 cycles compared to 9 and 5 months in those treated with ≤6 cycles ( p  &lt; 0.001). The disease control rate was 100% versus 56% in patients receiving &gt;6 and ≤6 cycles, respectively. No progression of disease was recorded in patients who received &gt;6 cycles. Grade 1 neuropathy and grade 3 neutropenia were more frequent in patients treated with &gt;6 cycles compared to patients receiving ≤6 cycles ( p  = 0.01;  p  = 0.03, respectively). Dose reduction was necessary for 70.1% and 53.4% of patients treated with &gt;6 or ≤6 cycles, whereas treatment interruption occurred in 37.1% and 21.6%, respectively. Our results confirmed the efficacy and safety of NABGEM in untreated mPC. In particular, we highlighted significant clinical efficacy in patients who received &gt;6 cycles of chemotherapy compared to those who received ≤6 cycles, with manageable toxicity profile.

Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine